NO2013010I2 - Aflibercept - Google Patents

Aflibercept

Info

Publication number
NO2013010I2
NO2013010I2 NO2013010C NO2013010C NO2013010I2 NO 2013010 I2 NO2013010 I2 NO 2013010I2 NO 2013010 C NO2013010 C NO 2013010C NO 2013010 C NO2013010 C NO 2013010C NO 2013010 I2 NO2013010 I2 NO 2013010I2
Authority
NO
Norway
Prior art keywords
aflibercept
macular degeneration
diabetic retinopathy
related macular
chimeric polypeptides
Prior art date
Application number
NO2013010C
Other languages
English (en)
Other versions
NO2013010I1 (no
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22480568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2013010(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of NO2013010I2 publication Critical patent/NO2013010I2/no
Publication of NO2013010I1 publication Critical patent/NO2013010I1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
NO2013010C 1999-06-08 2013-05-15 Aflibercept NO2013010I1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13813399P 1999-06-08 1999-06-08
PCT/US2000/014142 WO2000075319A1 (en) 1999-06-08 2000-05-23 Modified chimeric polypeptides with improved pharmacokinetic properties

Publications (2)

Publication Number Publication Date
NO2013010I2 true NO2013010I2 (no) 2013-05-15
NO2013010I1 NO2013010I1 (no) 2013-06-17

Family

ID=22480568

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20016036A NO330775B1 (no) 1999-06-08 2001-12-10 Isolert nukleinsyremolekyl som koder for vaskulaer endotelial vekstfaktor med immunoglobulin-domener, fusjonspolypeptid kodet av dette, fremgangsmate for fremstilling derav samt anvendelse derav
NO20100656A NO332559B1 (no) 1999-06-08 2010-05-06 Anvendelse av fusjonspolypeptid for fremstilling av medikamenter til behandling av oyesykdommer
NO2013010C NO2013010I1 (no) 1999-06-08 2013-05-15 Aflibercept

Family Applications Before (2)

Application Number Title Priority Date Filing Date
NO20016036A NO330775B1 (no) 1999-06-08 2001-12-10 Isolert nukleinsyremolekyl som koder for vaskulaer endotelial vekstfaktor med immunoglobulin-domener, fusjonspolypeptid kodet av dette, fremgangsmate for fremstilling derav samt anvendelse derav
NO20100656A NO332559B1 (no) 1999-06-08 2010-05-06 Anvendelse av fusjonspolypeptid for fremstilling av medikamenter til behandling av oyesykdommer

Country Status (33)

Country Link
EP (2) EP1544299B1 (no)
JP (2) JP4723140B2 (no)
KR (1) KR100659477B1 (no)
CN (3) CN100523187C (no)
AT (2) ATE417928T1 (no)
AU (2) AU779303B2 (no)
BE (1) BE2013C029I2 (no)
BR (2) BR0011407A (no)
CA (1) CA2376379C (no)
CY (2) CY1108883T1 (no)
CZ (2) CZ302689B6 (no)
DE (2) DE60019415T2 (no)
DK (2) DK1183353T3 (no)
ES (2) ES2237429T3 (no)
FR (1) FR13C0028I2 (no)
HK (3) HK1043388A1 (no)
HR (1) HRP20010908B1 (no)
HU (3) HU229156B1 (no)
IL (3) IL146890A0 (no)
LT (1) LTC1183353I2 (no)
LU (1) LU92195I2 (no)
ME (2) MEP3208A (no)
MX (1) MXPA01012630A (no)
NO (3) NO330775B1 (no)
NZ (1) NZ515913A (no)
PL (1) PL208247B1 (no)
PT (2) PT1183353E (no)
RS (1) RS50073B (no)
RU (1) RU2265661C2 (no)
SK (1) SK287332B6 (no)
UA (1) UA74146C2 (no)
WO (1) WO2000075319A1 (no)
ZA (1) ZA200110068B (no)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710174B2 (en) 2001-09-13 2004-03-23 Isis Pharmaceuticals, Inc. Antisense inhibition of vascular endothelial growth factor receptor-1 expression
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
ATE359300T1 (de) 2001-01-19 2007-05-15 Ludwig Inst Cancer Res Flt4 (vegfr-3) als ein ziel für krebs darstellung und anti-krebs-behandlung
US6734017B2 (en) 2001-09-28 2004-05-11 Isis Pharmaceuticals, Inc. Antisense modulation of vascular endothelial growth factor receptor-2 expression
EP2301564A1 (en) 2002-05-04 2011-03-30 Acorda Therapeutics, Inc. Compositions and methods for promoting neuronal outgrowth
PT1608685E (pt) * 2003-03-28 2007-05-31 Regeneron Pharma Anatagonistas de vegf para o tratamento de diabetes.
MX348062B (es) 2003-05-16 2017-05-26 Acorda Therapeutics Inc Mutantes que degradan proteoglicanos para tratamiento del snc.
EP1646353A4 (en) * 2003-05-16 2008-06-04 Acorda Therapeutics Inc FUSION PROTEINS FOR THE TREATMENT OF THE CENTRAL NERVOUS SYSTEM
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
EP1626989A2 (en) * 2003-05-28 2006-02-22 Regeneron Pharmaceuticals, Inc. Method of treating corneal transplant rejection by using vegf antagonists
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
EP1631317A2 (en) * 2003-06-06 2006-03-08 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for tumor regression
US7399612B2 (en) 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
AR046510A1 (es) 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
WO2005016369A1 (en) * 2003-08-06 2005-02-24 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist in combination with radiation therapy
ES2411504T3 (es) 2004-05-18 2013-07-05 Acorda Therapeutics, Inc. Métodos de purificación de condroitinasa y formulaciones estables de la misma
CA2569108C (en) * 2004-06-08 2012-08-21 Chengdu Kanghong Biotechnologies Co. Ltd Angiogenesis-inhibiting chimeric protein and the use
JP2008502738A (ja) 2004-06-10 2008-01-31 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトの癌を処置するための、ｖｅｇｆインヒビターの使用
MXPA06014689A (es) * 2004-06-18 2008-03-11 Regeneron Pharma Inhibidores del vegf para el tratamiento de efusion pleural maligna.
CN1997386B (zh) * 2004-07-30 2012-05-30 瑞泽恩制药公司 通过阻断vegf介导的活性来治疗i型糖尿病的方法
ES2407859T3 (es) 2004-09-13 2013-06-14 Genzyme Corporation Construcciones multiméricas.
FR2878749B1 (fr) * 2004-12-03 2007-12-21 Aventis Pharma Sa Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
US7303748B2 (en) 2005-02-02 2007-12-04 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a VEGF inhibitor
CA2598711C (en) 2005-03-25 2018-05-29 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations
JP5189985B2 (ja) 2005-09-26 2013-04-24 アコーダ セラピューティクス、インク． コンドロイチナーゼａｂｃｉ変異体を用いた組成物およびその使用方法
CA2630839C (en) † 2005-12-16 2017-01-17 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with dll4 antagonists
FR2895258B1 (fr) 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
CN100502945C (zh) * 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
DK2944306T3 (da) 2006-06-16 2021-03-08 Regeneron Pharma Egnede VEGF-antagonistformuleringer til intravitreal administration
BRPI0717431A2 (pt) 2006-09-29 2013-11-12 Oncomed Pharm Inc Composições e métodos de diagnóstico e tratamento do câncer
WO2008045970A2 (en) 2006-10-10 2008-04-17 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
FR2918279B1 (fr) * 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
CN101575379B (zh) * 2008-05-09 2012-05-30 上海抗体药物国家工程研究中心有限公司 可溶性vegfr双功能融合受体、其制备方法及用途
JP5954990B2 (ja) 2008-11-03 2016-07-20 モレキュラー・パートナーズ・アーゲーＭｏｌｅｃｕｌａｒ Ｐａｒｔｎｅｒｓ Ａｇ Ｖｅｇｆ−ａレセプター相互作用を阻害する結合タンパク質
CN101838329A (zh) 2009-03-18 2010-09-22 嘉和生物药业有限公司 抗血管新生融合蛋白
EP2488204B1 (en) 2009-10-16 2016-04-06 Oncomed Pharmaceuticals, Inc. Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
SI2601214T1 (en) 2010-08-06 2018-03-30 Genzyme Corporation VEGF antagonist compositions and their use
US20140080153A1 (en) * 2011-01-07 2014-03-20 Chugai Seiyaku Kabushiki Kaisha Method for improving physical properties of antibody
EP3222285A1 (en) 2011-01-13 2017-09-27 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
KR101397088B1 (ko) 2011-06-10 2014-05-19 강원대학교산학협력단 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
JO3370B1 (ar) * 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
BR112014013205A2 (pt) * 2011-12-01 2020-10-27 Protevobio, Inc. proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit
CN103304668B (zh) * 2012-03-12 2015-10-28 江苏健德生物药业有限公司 Ultra-VEGF-trap免疫融合蛋白、其制备方法及其应用
EP3646880A1 (en) 2012-05-07 2020-05-06 Allergan, Inc. Method of treating amd in patients refractory to anti-vegf therapy
WO2014006113A1 (en) 2012-07-03 2014-01-09 Sanofi Method of treating cancer by effective amounts of aflibercept
TW201438736A (zh) 2012-11-14 2014-10-16 Regeneron Pharma 以ｄｌｌ４拮抗劑治療卵巢癌之方法
AU2014218318B2 (en) 2013-02-18 2018-02-15 Vegenics Pty Limited Ligand binding molecules and uses thereof
AR095196A1 (es) * 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
CN104193828B (zh) * 2013-09-12 2017-04-05 北京韩美药品有限公司 同时阻断her2和vegfr信号通路的重组融合蛋白
PL3065761T3 (pl) 2013-11-05 2020-05-18 Allergan, Inc. Sposób leczenia schorzeń oczu za pomocą darpinu przeciwko vegf
AU2015260955B2 (en) 2014-05-12 2020-06-18 Formycon Ag Pre-filled plastic syringe containing a VEGF antagonist
EP3170005B1 (en) 2014-07-18 2019-04-10 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
JP2016036322A (ja) * 2014-08-11 2016-03-22 日本化薬株式会社 血管新生因子と結合するキメラタンパク質
EP3230316B1 (en) 2014-12-11 2022-01-05 Bayer HealthCare LLC Treatment of age related macular degeneration with a small active choroidal neovascularization lesion
GB201503453D0 (en) 2015-03-01 2015-04-15 Jain Arjun Endothelin-1"sponge"
TWI797060B (zh) 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
WO2017046140A1 (en) 2015-09-18 2017-03-23 Bayer Pharma Aktiengesellschaft Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
KR101936049B1 (ko) * 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
WO2017065559A1 (ko) 2015-10-15 2017-04-20 (주)알테오젠 Igg fc 도메인을 가지는 융합 단백질의 생산방법
AU2016358111B2 (en) 2015-11-18 2021-11-18 Formycon Ag Pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist
RU2751510C2 (ru) 2015-11-18 2021-07-14 Сио2 Медикал Продактс, Инк. Фармацевтическая упаковка для офтальмологических составов
CA3005692A1 (en) 2015-11-18 2017-05-26 Formycon Ag Pre-filled plastic syringe containing a vegf antagonist
WO2017084616A1 (en) * 2015-11-19 2017-05-26 Zhuhai Tairuishang Biopharm Ltd. Methods and compositions for binding vegf
AU2016364817B2 (en) 2015-12-03 2020-05-07 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
US10576128B2 (en) 2016-01-26 2020-03-03 Formycon Ag Liquid formulation of a VEGF antagonist
US20190300607A1 (en) 2016-10-12 2019-10-03 Daiichi Sankyo Company, Limited Composition containing anti-robo4 antibody and other agents
CA3043487A1 (en) 2016-11-21 2018-05-24 Just Biotherapeutics, Inc. Aflibercept formulations and uses thereof
US20200237997A1 (en) 2017-05-24 2020-07-30 Formycon Ag Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
CA3063995A1 (en) 2017-05-24 2018-11-29 Sio2 Medical Products, Inc. Sterilizable pharmaceutical package for ophthalmic formulations
WO2018215580A1 (en) 2017-05-24 2018-11-29 Formycon Ag Method for sterilizing prefilled plastic syringes containing a vegf antagonist
TW201904610A (zh) 2017-06-14 2019-02-01 德商拜耳製藥公司 用於治療新生血管型青光眼之非抗體vegf拮抗劑
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
ES2887046T3 (es) 2017-08-17 2021-12-21 Just Evotec Biologics Inc Método de purificación de proteína glicosilada a partir de galectinas de las células hospedadoras y otros contaminantes
WO2019099965A1 (en) 2017-11-20 2019-05-23 Just Biotherapeutics, Inc. Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
WO2019104279A1 (en) * 2017-11-27 2019-05-31 4D Molecular Therapeutics Inc. Adeno-associated virus variant capsids and use for inhibiting angiogenesis
PL3716992T3 (pl) 2017-11-30 2022-12-19 Regeneron Pharmaceuticals, Inc. Zastosowanie antagonisty vegf do leczenia angiogennych zaburzeń oka
WO2019118187A1 (en) 2017-12-13 2019-06-20 Regeneron Pharmaceuticals, Inc. Devices and systems for chromatography column bed support management and related methods
IL310376A (en) 2018-01-26 2024-03-01 Univ California Methods and preparations for the treatment of angiogenic disorders using anti-VEGF agents
WO2019217927A1 (en) 2018-05-10 2019-11-14 Regeneron Pharmaceuticals, Inc. High concentration vegf receptor fusion protein containing formulations
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
CN111378044B (zh) 2018-12-28 2022-07-15 长春金赛药业有限责任公司 抗体融合蛋白、制备方法及其应用
US20220204920A1 (en) 2019-05-16 2022-06-30 Formycon Ag Method for reducing methionine oxidation in recombinant proteins
US20210060258A1 (en) 2019-09-03 2021-03-04 Amgen Inc. Injection device for drug delivery and packaging for the injection device
CA3150482A1 (en) 2019-09-16 2021-03-25 Amgen Inc. Method for external sterilization of drug delivery device
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. METHOD FOR TREATING AN EYE DISORDER
BR112022010113A2 (pt) 2019-11-25 2022-09-06 Univ California Inibidores de vegf de longa ação para neovascularização intraocular
SG11202110968VA (en) * 2019-12-06 2021-10-28 Regeneron Pharma Anti-vegf protein compositions and methods for producing the same
EP4069264A1 (en) 2019-12-06 2022-10-12 Regeneron Pharmaceuticals, Inc. Vegf mini-traps and methods of use thereof
WO2021173603A1 (en) 2020-02-24 2021-09-02 Amgen Inc. Containers and systems for use during external sterilization of drug delivery devices
EP4145456A1 (en) 2021-09-06 2023-03-08 Bayer AG Prediction of a change related to a macular fluid
KR20240019034A (ko) * 2022-08-02 2024-02-14 주식회사 파노로스바이오사이언스 변형된 융합 단백질 및 이의 용도

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production

Also Published As

Publication number Publication date
MEP3208A (xx) 2010-02-10
DK1544299T3 (da) 2009-03-23
PL208247B1 (pl) 2011-04-29
HUP0201515A3 (en) 2004-12-28
JP2003501089A (ja) 2003-01-14
CY2013019I2 (el) 2015-11-04
AU5040400A (en) 2000-12-28
DK1183353T3 (da) 2005-08-08
ES2237429T3 (es) 2005-08-01
NO332559B1 (no) 2012-10-29
HRP20010908B1 (en) 2006-05-31
LTPA2013009I1 (lt) 2013-06-25
ZA200110068B (en) 2002-12-06
CN100523187C (zh) 2009-08-05
CN101433715B (zh) 2013-04-17
FR13C0028I2 (fr) 2014-05-16
KR20020019070A (ko) 2002-03-09
CY2013019I1 (el) 2015-11-04
DE60019415T2 (de) 2006-03-09
CA2376379A1 (en) 2000-12-14
EP1183353A1 (en) 2002-03-06
DE60019415D1 (de) 2005-05-19
BRPI0011407B1 (pt) 2018-09-25
YU86901A (sh) 2004-05-12
HK1185798A1 (en) 2014-02-28
CA2376379C (en) 2007-08-07
UA74146C2 (uk) 2005-11-15
LU92195I2 (fr) 2013-07-15
ATE293164T1 (de) 2005-04-15
EP1183353B1 (en) 2005-04-13
NO330775B1 (no) 2011-07-11
MXPA01012630A (es) 2002-07-22
BR0011407A (pt) 2002-04-02
HUP0201515A2 (en) 2002-08-28
JP2011024595A (ja) 2011-02-10
EP1544299B1 (en) 2008-12-17
ATE417928T1 (de) 2009-01-15
AU2005201365A1 (en) 2005-04-28
HRP20010908A2 (en) 2005-04-30
CN101433715A (zh) 2009-05-20
PT1183353E (pt) 2005-06-30
AU779303B2 (en) 2005-01-13
CY1108883T1 (el) 2014-07-02
IL146890A (en) 2008-07-08
NO2013010I1 (no) 2013-06-17
SK17522001A3 (sk) 2003-04-01
KR100659477B1 (ko) 2006-12-20
HU229156B1 (en) 2013-09-30
CN103349781A (zh) 2013-10-16
CN1369009A (zh) 2002-09-11
WO2000075319A1 (en) 2000-12-14
JP5273746B2 (ja) 2013-08-28
NO20016036D0 (no) 2001-12-10
HU230159B1 (hu) 2015-09-28
NO20100656L (no) 2002-02-08
BRPI0011407B8 (pt) 2021-05-25
JP4723140B2 (ja) 2011-07-13
CZ20014387A3 (cs) 2002-10-16
HK1043388A1 (en) 2002-09-13
CZ302689B6 (cs) 2011-09-07
ES2319305T3 (es) 2009-05-06
SK287332B6 (sk) 2010-07-07
HK1132653A1 (en) 2010-03-05
LTC1183353I2 (lt) 2023-02-27
RU2265661C2 (ru) 2005-12-10
CN103349781B (zh) 2015-04-01
ME00024B (me) 2010-02-10
NO20016036L (no) 2002-02-08
FR13C0028I1 (fr) 2013-06-14
NZ515913A (en) 2004-01-30
HUS1300052I1 (hu) 2016-08-29
RS50073B (sr) 2009-01-22
AU2005201365B2 (en) 2007-08-09
PL352246A1 (en) 2003-08-11
EP1544299A1 (en) 2005-06-22
DE60041159D1 (de) 2009-01-29
PT1544299E (pt) 2009-03-18
IL146890A0 (en) 2002-08-14
CZ303656B6 (cs) 2013-01-30
BE2013C029I2 (no) 2019-03-06
IL190234A0 (en) 2008-11-03

Similar Documents

Publication Publication Date Title
NO2013010I2 (no) Aflibercept
MXPA02001911A (es) Anticuerpos ctla-4 humanos y sus usos.
ATE396738T1 (de) Verwendung von glp-2-peptiden
ATE323684T1 (de) Verfahren und zusammensetzungen unter verwendung von chinazolinonen
DE60136272D1 (de) Diagnostika und therapeutika für makula degeneration erkrankungen
DE60042066D1 (de) Chimärische dr4 antikörper und ihre verwendung
NO992916L (no) Fosfodiesterase 8A
PL1694354T3 (pl) Sposób zapobiegania i leczenia cukrzycy za pomocą neurturyny
WO2006091666A3 (en) Methods and compositions for treating conditions of the eye
DE60130798D1 (de) "alpha1-untereinheit des natriumkanals, polypeptide davon und deren verwendung zur behandlung von generalisierter epilepsie mit fieberanfällen plus "
ATE319819T1 (de) Humane hirn-spezifische carboxypeptidase b
TR199501276A2 (tr) Sübstitüe edilmis sikloalkilamino-ve-alkoksi-heterosaykillar, üretilmelerine mahsus usul ve zararlilarla mücadele maddesi olarak kullanilmalari.
BR9909473B1 (pt) composição herbicida, e, processo para controlar ervas daninhas.

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: REGENERON PHARMACEUTICALS INC, US